Old Web
English
Sign In
Acemap
>
authorDetail
>
James Vanderlugt
James Vanderlugt
Esperion Therapeutics Inc.
Endocrinology
Medicine
Internal medicine
ldl cholesterol
Diabetes mellitus
3
Papers
3
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
ETC-1002 Rapidly and Significantly Reduces LDL-Cholesterol and is Well Tolerated in Healthy Subjects†
2013
Journal of Clinical Lipidology
Noah Rosenberg
Jeffrey C. Hanselman
Diane MacDougall
Janice R. Margulies
Scott McBride
Mark Milad
Lorenzo A. DiCarlo
James Vanderlugt
Roger S. Newton
Show All
Source
Cite
Save
Citations (0)
ETC-1002, A MODULATOR OF ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE AND ADENOSINE TRIPHOSPHATE-CITRATE LYASE, WAS SAFE AND REDUCED LOW-DENSITY LIPOPROTEIN-CHOLESTEROL IN HEALTHY VOLUNTEERS
2013
Journal of the American College of Cardiology
Diane MacDougall
James Vanderlugt
Noah Rosenberg
Lorenzo A. DiCarlo
Mark Milad
Janice R. Margulies
Roger S. Newton
Show All
Source
Cite
Save
Citations (3)
ETC-1002 Lowers LDL-Cholesterol and Beneficially Modulates Other Cardio-Metabolic Risk Factors in Hypercholesterolemic Subjects†
2013
Journal of Clinical Lipidology
Noah Rosenberg
Diane MacDougall
Jeffrey C. Hanselman
Mark Milad
Scott McBride
Lorenzo A. DiCarlo
Roger S. Newton
Christie M. Ballantyne
Michael Davidson
Randall Severance
James M. McKenney
James Vanderlugt
Harold E. Bays
John Rubino
Stephen Wayne Halpern
Linda Gaudiani
Michael J. Koren
Jennifer G. Robinson
Show All
Source
Cite
Save
Citations (0)
1